{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:54:14Z","timestamp":1793760854537,"version":"4.6.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.toxicon.2025.108666","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:35:13Z","timestamp":1763771713000},"page":"108666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Two-year real-world retrospective safety evaluation with onabotulinumtoxinA across multiple therapeutic indications: Findings from the SYNCHRONIZE study"],"prefix":"10.1016","volume":"269","author":[{"given":"Grace","family":"Forde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly Becker","family":"Ifantides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeli","family":"Mayadev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2765-7953","authenticated-orcid":false,"given":"Atul T.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Rhyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahunna","family":"Ukah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7052-9243","authenticated-orcid":false,"given":"Simona","family":"Battucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.toxicon.2025.108666_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/toxins12020127","article-title":"Efficacy and safety of OnabotulinumtoxinA 400 units in patients with post-stroke upper limb spasticity: final report of a randomized, double-blind, placebo-controlled trial with an open-label extension phase","volume":"12","author":"Abo","year":"2020","journal-title":"Toxins"},{"issue":"1","key":"10.1016\/j.toxicon.2025.108666_bib2","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1212\/WNL.0000000000006688","article-title":"High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy","volume":"92","author":"Albrecht","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.toxicon.2025.108666_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/toxins13010042","article-title":"Botulinum toxin in movement disorders: an update","volume":"13","author":"Anandan","year":"2021","journal-title":"Toxins"},{"issue":"13","key":"10.1016\/j.toxicon.2025.108666_bib4","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1212\/01.wnl.0000327865.05877.17","article-title":"Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A","volume":"71","author":"Atassi","year":"2008","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.toxicon.2025.108666_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/ane.12171","article-title":"OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program","volume":"129","author":"Aurora","year":"2014","journal-title":"Acta Neurol. Scand."},{"issue":"9","key":"10.1016\/j.toxicon.2025.108666_bib6","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00702-015-1384-6","article-title":"High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis","volume":"122","author":"Baricich","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.toxicon.2025.108666_bib7","article-title":"Pain, disability, and quality of life in participants after concurrent onabotulinumtoxinA treatment of upper and lower limb spasticity: observational results from the ASPIRE study","author":"Bavikatte","year":"2024","journal-title":"Pharm. Manag. PM R"},{"issue":"7","key":"10.1016\/j.toxicon.2025.108666_bib8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/PHM.0000000000002410","article-title":"Safety and real-world dosing of OnabotulinumtoxinA for the treatment of adult spasticity: post hoc analysis of the adult spasticity international registry study","volume":"103","author":"Bavikatte","year":"2024","journal-title":"Am. J. Phys. Med. Rehabil."},{"issue":"9","key":"10.1016\/j.toxicon.2025.108666_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/toxins11090491","article-title":"Immunogenicity associated with botulinum toxin treatment","volume":"11","author":"Bellows","year":"2019","journal-title":"Toxins"},{"issue":"S1","key":"10.1016\/j.toxicon.2025.108666_bib11","article-title":"Entering the 4th decade of Botox (onabotulinumtoxinA): a narrative review of its development and impact on patients and medicine","volume":"102","author":"Brin","year":"2023","journal-title":"Medicine (Baltim.)"},{"issue":"S1","key":"10.1016\/j.toxicon.2025.108666_bib12","article-title":"Botox (onabotulinumtoxinA) mechanism of action","volume":"102","author":"Brin","year":"2023","journal-title":"Medicine (Baltim.)"},{"issue":"7","key":"10.1016\/j.toxicon.2025.108666_bib13","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of action of OnabotulinumtoxinA in chronic migraine: a narrative review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.toxicon.2025.108666_bib14","article-title":"High-dose botulinum toxin therapy: safety, benefit, and endurance of efficacy","volume":"10","author":"Chiu","year":"2020","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"10.1016\/j.toxicon.2025.108666_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.07.031","article-title":"Minimal clinically important change in patients with cervical dystonia: results from the CD PROBE study","volume":"405","author":"Dashtipour","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.toxicon.2025.108666_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2024.108035","article-title":"Treatment response to onabotulinumtoxinA in cervical dystonia patients with anterocollis and retrocollis","volume":"248","author":"Dashtipour","year":"2024","journal-title":"Toxicon"},{"issue":"7","key":"10.1016\/j.toxicon.2025.108666_bib17","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40265-024-02048-x","article-title":"Botulinum Toxin-A for the treatment of myogenous temporomandibular disorders: an umbrella review of systematic reviews","volume":"84","author":"De la Torre Canales","year":"2024","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.toxicon.2025.108666_bib18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00126839-200809030-00002","article-title":"Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting","volume":"9","author":"Dowson","year":"2008","journal-title":"Drugs R&D"},{"issue":"10","key":"10.1016\/j.toxicon.2025.108666_bib19","first-page":"960","article-title":"OnabotulinumtoxinA for lower limb spasticity: guidance from a Delphi panel approach","volume":"9","author":"Esquenazi","year":"2017","journal-title":"Pharm. Manag. PM R"},{"issue":"10","key":"10.1016\/j.toxicon.2025.108666_bib20","first-page":"1079","article-title":"Long-term observational results from the ASPIRE study: onabotulinumtoxina treatment for adult lower limb spasticity","volume":"13","author":"Esquenazi","year":"2021","journal-title":"Pharm. Manag. PM R"},{"issue":"S1","key":"10.1016\/j.toxicon.2025.108666_bib21","article-title":"Treatment of adult spasticity with Botox (onabotulinumtoxinA): development, insights, and impact","volume":"102","author":"Esquenazi","year":"2023","journal-title":"Medicine (Baltim.)"},{"issue":"10","key":"10.1016\/j.toxicon.2025.108666_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/toxins16100420","article-title":"SYNCHRONIZE: real-world retrospective safety analysis of patients treated with OnabotulinumtoxinA for more than one therapeutic indication","volume":"16","author":"Forde","year":"2024","journal-title":"Toxins"},{"issue":"8","key":"10.1016\/j.toxicon.2025.108666_bib23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2340\/16501977-2245","article-title":"Adult spasticity international registry study: methodology and baseline patient, healthcare provider, and caregiver characteristics","volume":"49","author":"Francisco","year":"2017","journal-title":"J. Rehabil. Med."},{"issue":"11","key":"10.1016\/j.toxicon.2025.108666_bib24","first-page":"1120","article-title":"Individualized OnabotulinumtoxinA treatment for upper limb spasticity resulted in high Clinician- and patient-reported satisfaction: long-term observational results from the ASPIRE study","volume":"12","author":"Francisco","year":"2020","journal-title":"Pharm. Manag. PM R"},{"issue":"5","key":"10.1016\/j.toxicon.2025.108666_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/toxins12050315","article-title":"High dosage of botulinum toxin type A in adult subjects with spasticity following acquired central nervous system damage: where are we at?","volume":"12","author":"Intiso","year":"2020","journal-title":"Toxins"},{"issue":"8","key":"10.1016\/j.toxicon.2025.108666_bib26","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.27072","article-title":"Botulinum toxin: state of the art","volume":"32","author":"Jankovic","year":"2017","journal-title":"Mov. Disord."},{"issue":"1\u20132","key":"10.1016\/j.toxicon.2025.108666_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2014.12.030","article-title":"Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE)","volume":"349","author":"Jankovic","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.toxicon.2025.108666_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/toxins15050342","article-title":"Neutralizing antibody formation with OnabotulinumtoxinA (BOTOX((R))) treatment from global registration studies across multiple indications: a meta-analysis","volume":"15","author":"Jankovic","year":"2023","journal-title":"Toxins"},{"issue":"4","key":"10.1016\/j.toxicon.2025.108666_bib29","first-page":"349","article-title":"Adverse event profiles of high dose botulinum toxin injections for spasticity","volume":"12","author":"Kirshblum","year":"2020","journal-title":"Pharm. Manag. PM R"},{"issue":"7","key":"10.1016\/j.toxicon.2025.108666_bib30","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1185\/030079904125003962","article-title":"Safety of botulinum toxin type A: a systematic review and meta-analysis","volume":"20","author":"Naumann","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"issue":"Suppl 4","key":"10.1016\/j.toxicon.2025.108666_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1468-1331.2006.01652.x","article-title":"Safety and efficacy of botulinum toxin type A following long-term use","volume":"13","author":"Naumann","year":"2006","journal-title":"Eur. J. Neurol."},{"issue":"13","key":"10.1016\/j.toxicon.2025.108666_bib32","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/mds.23254","article-title":"Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX(R)) across multiple indications","volume":"25","author":"Naumann","year":"2010","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.toxicon.2025.108666_bib33","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.urology.2014.07.046","article-title":"Incidence of adverse events after high doses of onabotulinumtoxinA for multiple indications","volume":"84","author":"Nuanthaisong","year":"2014","journal-title":"Urology"},{"issue":"1\u20132","key":"10.1016\/j.toxicon.2025.108666_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2015.01.033","article-title":"Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke","volume":"350","author":"Santamato","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"13","key":"10.1016\/j.toxicon.2025.108666_bib35","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40265-017-0786-1","article-title":"Benefits and risks of non-approved injection regimens for botulinum toxins in spasticity","volume":"77","author":"Santamato","year":"2017","journal-title":"Drugs"},{"issue":"S1","key":"10.1016\/j.toxicon.2025.108666_bib36","article-title":"Treatment of chronic migraine with Botox (onabotulinumtoxinA): development, insights, and impact","volume":"102","author":"Turkel","year":"2023","journal-title":"Medicine (Baltim.)"},{"issue":"6","key":"10.1016\/j.toxicon.2025.108666_bib37","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1017\/cjn.2019.238","article-title":"Long-term safety and dosing of OnabotulinumtoxinA: a prospective, observational study","volume":"46","author":"Wein","year":"2019","journal-title":"Can. J. Neurol. Sci."},{"issue":"8","key":"10.1016\/j.toxicon.2025.108666_bib38","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1526-4610.2012.02164.x","article-title":"Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine","volume":"52","author":"Winner","year":"2012","journal-title":"Headache"},{"issue":"8","key":"10.1016\/j.toxicon.2025.108666_bib39","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s40264-019-00824-3","article-title":"Long-term safety and tolerability of OnabotulinumtoxinA treatment in patients with chronic migraine: results of the COMPEL study","volume":"42","author":"Winner","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.toxicon.2025.108666_bib40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.toxicon.2018.01.018","article-title":"Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity - insights from recent studies","volume":"147","author":"Wissel","year":"2018","journal-title":"Toxicon"}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010125004416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010125004416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T04:57:46Z","timestamp":1770008266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010125004416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":39,"alternative-id":["S0041010125004416"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2025.108666","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two-year real-world retrospective safety evaluation with onabotulinumtoxinA across multiple therapeutic indications: Findings from the SYNCHRONIZE study","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2025.108666","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108666"}}